导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.58% | 1497/4773 |
| 近一周 | -1.19% | 2251/5467 |
| 近一月 | -11.76% | 5110/5421 |
| 近一季 | -20.71% | 4868/5238 |
| 近半年 | 1.19% | 1359/4931 |
| 近一年 | 5.58% | 1503/4400 |
| 近两年 | 118.87% | 430/2954 |
| 近三年 | 69.98% | 340/2253 |
| 成立以来 | 116.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.60% 1878/4961 |
37.01% 861/5312 |
- - |
- - |
| 2025 | 51.40% 437/4813 |
-1.65% 2727/3635 |
3.28% 1068/4076 |
50.52% 301/4524 |
-0.97% 2754/4813 |
| 2024 | 14.36% 1053/3463 |
-3.85% 1570/2808 |
-6.62% 1986/3014 |
29.27% 169/3129 |
-1.46% 1712/3463 |
| 2023 | -18.63% 1819/2656 |
2.20% 1411/2280 |
-7.08% 1771/2385 |
-9.54% 1846/2515 |
-5.28% 1311/2655 |
| 2022 | -28.68% 1574/2207 |
-19.86% 1500/1919 |
6.15% 760/2016 |
-18.34% 1697/2113 |
2.65% 869/2208 |
| 2021 | 15.65% 301/1822 |
-6.21% 985/1255 |
27.41% 63/1330 |
-5.74% 853/1466 |
2.68% 538/1822 |
| 2020 | 69.20% 77/1250 |
4.21% 81/1028 |
30.62% 50/1067 |
7.12% 802/1164 |
16.04% 186/1184 |
| 2019 | 45.22% 155/1092 |
35.10% 101/754 |
-9.59% 671/804 |
7.75% 78/850 |
10.34% 146/918 |
| 2018 | -26.71% 394/834 |
- - |
- - |
- - |
-11.11% 250/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏创业板ETF VS. 长安沪深300非周期A(740101) |